Source: Elanco Animal Health
The Codex Alimentarius Commission has adopted global food safety standards for ractopamine hydrochloride (ractopamine) at its 35th Session in Rome. “These standards provide an international food safety reference point that helps assure consumers that their food is safe. Codex standards for ractopamine are a significant step toward enabling sustainable meat production, fulfilling the increased demand for animal protein and therefore addressing worldwide hunger,” stated Jeff Simmons, President, Elanco Animal Health.
Ractopamine is a feed ingredient that directs nutrients from fat to lean protein, helping increase the yield of lean meat from pigs and cattle. It is a synthetic organic compound, not an antibiotic nor a steroid hormone.
Simmons added, “Elanco is very pleased with today’s official adoption of the standards by the Commission and is grateful for the numerous countries that supported it.”
The Commission adopted an Acceptable Daily Intake (ADI) and Maximum Residue Levels (MRLs) for pig and cattle tissues (muscle, fat, liver and kidney). The human safety of meat products derived from pigs and cattle fed ractopamine had been confirmed three times by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 2004, 2006 and 2010 and by 27 regulatory authorities from around the world.1,2,3Adoption by Codex of an ADI and the MRLs proposed by JECFA helps countries to produce, export, and import foods that are safe, and to verify their safety.
Ractopamine is commercially available from Elanco as Paylean® and Optaflexx®, respectively swine and cattle feed ingredients that direct nutrients to improve carcass leanness, increase average daily gain and improve feed efficiency.
The Commission also decided to hold the global food safety standards for recombinant bovine somatotropin (rBST) at Step 8 of its adoption procedure. The Commission decided to update the most recent scientific information related to human safety, supporting a food safety standard for rBST before adoption, and asked the Joint FAO/WHO Expert Committee on Food Additives (JECFA) to conduct an evaluation of the new information. JECFA has already twice evaluated and confirmed the human safety of rBST.
rBST is a supplement that increases milk production in healthy lactating cows, allowing farmers to produce safe, nutritious milk that is not only more affordable because of efficient farming practices, but is also produced in a more environmentally responsible way. Milk from rBST-supplemented cows, like all milk – organic, conventional, or rBST free – is a good and wholesome source of vital nutrients.
The Commission also adopted global food safety standards for narasin for pigs and monensin for cattle. Narasin is a feed additive that improves feed efficiency. Monensin is a feed additive with indications including coccidiosis, bloat prevention, ketosis or feed efficiency according to the country of registration. Adoption of standards for narasin and monensin further underscores Elanco’s long-term commitment to supporting JECFA scientific assessments and the importance of establishing global food safety standards via Codex.
Paylean® for swine and Optaflexx® for cattle are trademarks for Elanco’s brands of ractopamine hydrochloride. Posilac®, Lactotropina®, Lactotropin®, Lactatropin® and Somatech® are registered trademarks for Elanco’s brands of recombinant bovine somatotropin. Monteban® is the registered trademark for Elanco’s brand of narasin for swine. Rumensin® is the registered trademark for Elanco’s brand of monensin for cattle. The product labels contain complete use information including cautions and warnings. Always read, understand and follow the label and use directions. Product availability and use restrictions vary by country. To consult individual
Elanco offices or websites for detailed product information, click here.
Elanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 2,500 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available here.